ES2319563T3 - Uso de (11beta, 17beta)-11-(1.3-benzodioxol-5-il)-17-hidroxi-17-(1-propinil)estra-4,9-dien-3-ona para el tratamiento del trastorno por depresion mayor. - Google Patents
Uso de (11beta, 17beta)-11-(1.3-benzodioxol-5-il)-17-hidroxi-17-(1-propinil)estra-4,9-dien-3-ona para el tratamiento del trastorno por depresion mayor. Download PDFInfo
- Publication number
- ES2319563T3 ES2319563T3 ES06101005T ES06101005T ES2319563T3 ES 2319563 T3 ES2319563 T3 ES 2319563T3 ES 06101005 T ES06101005 T ES 06101005T ES 06101005 T ES06101005 T ES 06101005T ES 2319563 T3 ES2319563 T3 ES 2319563T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- org
- estra
- depression
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 22
- 208000024714 major depressive disease Diseases 0.000 title claims abstract description 15
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 46
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- -1 1,3-benzodioxol-5-yl Chemical group 0.000 claims abstract description 10
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 claims abstract description 8
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 9
- 230000001629 suppression Effects 0.000 claims description 6
- DFELGYQKEOCHOA-BZAFBGKRSA-N (8s,11r,13s,14s,17s)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=C1 DFELGYQKEOCHOA-BZAFBGKRSA-N 0.000 description 19
- 230000001430 anti-depressive effect Effects 0.000 description 11
- 239000000935 antidepressant agent Substances 0.000 description 10
- 229940005513 antidepressants Drugs 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000003862 glucocorticoid Substances 0.000 description 10
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 8
- 229960003248 mifepristone Drugs 0.000 description 8
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 7
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 229960002296 paroxetine Drugs 0.000 description 7
- 150000003431 steroids Chemical class 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 101800000414 Corticotropin Proteins 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 4
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 3
- 208000014311 Cushing syndrome Diseases 0.000 description 3
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 3
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010048675 Pituitary enlargement Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002800 anti-glucocorticoid effect Effects 0.000 description 1
- 230000001838 anti-progestagenic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000009907 neuroendocrine response Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940023942 remeron Drugs 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01204072 | 2001-10-26 | ||
| EP01204072 | 2001-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2319563T3 true ES2319563T3 (es) | 2009-05-08 |
Family
ID=8181136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06101005T Expired - Lifetime ES2319563T3 (es) | 2001-10-26 | 2002-10-21 | Uso de (11beta, 17beta)-11-(1.3-benzodioxol-5-il)-17-hidroxi-17-(1-propinil)estra-4,9-dien-3-ona para el tratamiento del trastorno por depresion mayor. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20040266863A1 (https=) |
| EP (2) | EP1652526B1 (https=) |
| JP (1) | JP4647909B2 (https=) |
| KR (1) | KR20050038580A (https=) |
| CN (1) | CN100531738C (https=) |
| AT (2) | ATE317700T1 (https=) |
| AU (1) | AU2002348996B2 (https=) |
| BR (1) | BR0213466A (https=) |
| CA (1) | CA2463446C (https=) |
| CY (1) | CY1110173T1 (https=) |
| DE (2) | DE60230936D1 (https=) |
| DK (1) | DK1652526T3 (https=) |
| EC (1) | ECSP045080A (https=) |
| ES (1) | ES2319563T3 (https=) |
| HR (1) | HRP20040370B1 (https=) |
| HU (1) | HUP0500070A3 (https=) |
| IL (2) | IL161248A0 (https=) |
| IS (1) | IS2702B (https=) |
| MX (1) | MXPA04003781A (https=) |
| NO (1) | NO332978B1 (https=) |
| NZ (1) | NZ532429A (https=) |
| PL (1) | PL206687B1 (https=) |
| PT (1) | PT1652526E (https=) |
| RU (1) | RU2302245C2 (https=) |
| WO (1) | WO2003037354A1 (https=) |
| ZA (1) | ZA200403088B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050080061A1 (en) * | 2003-07-23 | 2005-04-14 | Corcept Therapeutics, Inc. | Antiglucocorticoid therapy for the prevention of neurological damage in premature infants |
| BRPI0517847A (pt) * | 2004-11-19 | 2008-10-21 | Organon Nv | combinação, usos de um inibidor de reabsorção de serotonina seletiva e de um antagonista do receptor de glicocorticóide, e, método para o tratamento de um indivìduo de uma espécie vertebrada sofrendo de depressão ou um distúrbio relacionado |
| AU2011236053B2 (en) * | 2004-11-19 | 2014-06-26 | Merck Sharpe & Dohme B.V. | Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression |
| WO2007131041A2 (en) * | 2006-05-02 | 2007-11-15 | Corcept Therapeutics, Inc. | The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2 |
| WO2012106514A2 (en) * | 2011-02-03 | 2012-08-09 | Pop Test Cortisol Llc | System and method for diagnosis and treatment |
| WO2012145258A1 (en) * | 2011-04-18 | 2012-10-26 | Pop Test Cortisol Llc | Hair loss treatment |
| US8986677B2 (en) * | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814333A (en) * | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| DE4447401A1 (de) * | 1994-12-23 | 1996-07-04 | Schering Ag | 14,17-C¶2¶-überbrückte Steroide |
| IL118974A (en) * | 1995-08-17 | 2001-09-13 | Akzo Nobel Nv | History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them |
| DE19727772A1 (de) * | 1997-06-30 | 1999-01-28 | Forschungszentrum Juelich Gmbh | Magnetflußsensor mit ringförmiger Sonde |
| AU747956B2 (en) * | 1997-10-06 | 2002-05-30 | Board Of Trustees Of The Leland Stanford Junior University | Methods for treating psychosis associated with glucocorticoid related dysfunction |
| DE60232956D1 (de) * | 2001-03-23 | 2009-08-27 | Corcept Therapeutics Inc | Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten |
| WO2002096433A1 (en) * | 2001-05-04 | 2002-12-05 | Corcept Therapeutics, Inc. | Methods for treating delirium using glucocorticoid receptor-specific antagonists |
| NZ531477A (en) * | 2001-08-31 | 2006-10-27 | Corcept Therapeutics Inc | Use of a glucocorticoid receptor antagonist comprising a steroidal skeleton with at least one phenyl-containing moiety in the 11-beta position of the steroidal skeleton to decrease cognitive deterioration in adults with Down's syndrome |
-
2002
- 2002-10-21 DE DE60230936T patent/DE60230936D1/de not_active Expired - Lifetime
- 2002-10-21 AU AU2002348996A patent/AU2002348996B2/en not_active Ceased
- 2002-10-21 WO PCT/EP2002/011732 patent/WO2003037354A1/en not_active Ceased
- 2002-10-21 CA CA2463446A patent/CA2463446C/en not_active Expired - Fee Related
- 2002-10-21 MX MXPA04003781A patent/MXPA04003781A/es active IP Right Grant
- 2002-10-21 RU RU2004116082/15A patent/RU2302245C2/ru not_active IP Right Cessation
- 2002-10-21 HR HRP20040370AA patent/HRP20040370B1/xx not_active IP Right Cessation
- 2002-10-21 BR BR0213466-7A patent/BR0213466A/pt not_active IP Right Cessation
- 2002-10-21 JP JP2003539697A patent/JP4647909B2/ja not_active Expired - Fee Related
- 2002-10-21 DE DE60209248T patent/DE60209248D1/de not_active Expired - Lifetime
- 2002-10-21 EP EP06101005A patent/EP1652526B1/en not_active Expired - Lifetime
- 2002-10-21 DK DK06101005T patent/DK1652526T3/da active
- 2002-10-21 AT AT02781273T patent/ATE317700T1/de active
- 2002-10-21 PT PT06101005T patent/PT1652526E/pt unknown
- 2002-10-21 ES ES06101005T patent/ES2319563T3/es not_active Expired - Lifetime
- 2002-10-21 KR KR1020047006050A patent/KR20050038580A/ko not_active Ceased
- 2002-10-21 CN CNB028210417A patent/CN100531738C/zh not_active Expired - Fee Related
- 2002-10-21 PL PL369261A patent/PL206687B1/pl not_active IP Right Cessation
- 2002-10-21 EP EP02781273A patent/EP1441739B1/en not_active Expired - Lifetime
- 2002-10-21 IL IL16124802A patent/IL161248A0/xx unknown
- 2002-10-21 AT AT06101005T patent/ATE420649T1/de active
- 2002-10-21 US US10/493,981 patent/US20040266863A1/en not_active Abandoned
- 2002-10-21 HU HU0500070A patent/HUP0500070A3/hu unknown
- 2002-10-21 NZ NZ532429A patent/NZ532429A/en not_active IP Right Cessation
-
2004
- 2004-03-31 IS IS7204A patent/IS2702B/is unknown
- 2004-04-01 IL IL161248A patent/IL161248A/en not_active IP Right Cessation
- 2004-04-22 ZA ZA200403088A patent/ZA200403088B/en unknown
- 2004-04-23 EC EC2004005080A patent/ECSP045080A/es unknown
- 2004-04-23 NO NO20041651A patent/NO332978B1/no not_active IP Right Cessation
-
2009
- 2009-02-02 CY CY20091100116T patent/CY1110173T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GAILLARD et al. | RU 486 inhibits peripheral effects of glucocorticoids in humans | |
| AU616208B2 (en) | Compounds having antiprogestational and anti-estrogenic activities for induction of labor and for termination of pregnancy, as well as for the treatment of gynaecological disorders | |
| ES2814343T3 (es) | Composiciones y métodos para suprimir las proliferaciones endometriales | |
| Van Heusden et al. | Residual ovarian activity during oral steroid contraception | |
| KR100385663B1 (ko) | 여성피임용으로함께사용될수있는프로게스테론길항작용및항에스트로겐작용이있는화합물 | |
| ES2319563T3 (es) | Uso de (11beta, 17beta)-11-(1.3-benzodioxol-5-il)-17-hidroxi-17-(1-propinil)estra-4,9-dien-3-ona para el tratamiento del trastorno por depresion mayor. | |
| JP2006502997A (ja) | アンドロゲン１１β‐ハロゲンステロイドおよびゲスタゲンを含有する組成物ならびにこの組成物に基づく男性用避妊薬 | |
| Rapkin et al. | Oral contraceptives and neuroactive steroids | |
| ES2314103T3 (es) | Metodo para inhibir deterioro cognitivo en adultos con sindrome de down. | |
| ES2279515T3 (es) | Antagonistas competitivos de la progesterona para el control de la fertilidad femenina, orientado a las necesidades de uso. | |
| US8193172B2 (en) | Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists | |
| AU2002348996A1 (en) | Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatement of major depressive disorder | |
| HK1087357B (en) | Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder | |
| EP1605924B1 (en) | Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) | |
| Loriaux¹ | Lynnette K. Nieman, 1 George rge P. Chrousos, 1 Charles | |
| TW200950788A (en) | Compositions and methods for male contraception | |
| US20050124592A1 (en) | Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen | |
| ANTI-PROGESTERONE | CC Chang, 1 Sheldon J. Segal, 2 and C. Wayne Bardin¹ |